Dr. Bazhenova on the Challenges of Second-Line Therapy in SCLC

Video

Lyudmila A. Bazhenova, MD, discusses the challenges of second-line therapy in small cell lung cancer.

Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, Moores Cancer Center, University of California San Diego Health, discusses the challenges of second-line therapy in small cell lung cancer (SCLC).

Most patients with SCLC have a lower performance status because they typically have multiple comorbidities, Bazhenova says. Due to lower performance status, some patients will not be fit enough to undergo second-line therapy, Bazhenova explains. 

The emergence of more viable treatment options in the first-line setting could improve the number of patients capable of receiving second-line treatment, Bazhenova continues. By developing more efficacious and tolerable first-line treatments, patients will be more fit when they experience disease progression, Bazhenova concludes.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center